| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | CEO | President & CEO +3 more
4 companies
Edward M. Kaye MD is Director at STOK, with reported holdings spanning 4 companies. From February 2015 to October 2026, the filings on record show 1 open-market purchase and 30 sales. Edward M. Kaye MD's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $5.4M at current prices.
Our model assigns Edward M. Kaye MD a below-average insider score of 45/100, based on 26 past trades. Over a 12-month horizon, 16.7% of those trades were profitable, with an average 12-month return of -42.0%.
Edward M. Kaye MD's largest disclosed position is in STOK as Director, worth about $3.4M. The STOK filings lean toward selling, a net 320,351 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2015 | SRPT Sarepta Therapeutics, Inc. | SVP & Chief Medical Officer | Buy | 800 | $11.82 | $9,452.00 | +156.6% |